Laurence Albiges

Medical Oncologist - GU oncology; Chair Med Onc Dpmt @gustaveroussy ; Professor of medecine @UniversiteParisSaclay #kidneycancer #RCC views are mine

[Laurence Albiges @AlbigesL]

@GEVaughan1 Many Thanks Gretchen !!!

[Laurence Albiges @AlbigesL]

@montypal Amazing keynote lecture at #ARTuR25 ! thanks for sharing your vision of #RCC futur
@MejeanArnaud @UrologieParis @DrChoueiri @AFUrologie @uroccr

[CancerNetwork® @CancerNetwrk]

Among all evaluable patients who received pembrolizumab/lenvatinib, the ORR was 50.6% (95% CI, 42.6%-58.7%), a DCR of 82.3% (95% CI, 75.4%-87.9%), and a CBR of 71.5% (95% CI, 63.8%-78.4%). #kicsm #KCRS2025 | @kidneycan @AlbigesL

https://t.co/dMgRozzFha

[Laurence Albiges @AlbigesL]

@GEVaughan1 Many thanks for the kind words !

[Laurence Albiges @AlbigesL]

Thanks #ASCO25 for the amazing opportunity to present some of the @GustaveRoussy works

@FAndreMD @barlesi @drcmassard @BenjaminBesseMD @dplanchard @BarbaraPistill2 @EmelineColomba @JordiRemon @HollebecqueA @Ribeiro2M @MichelsJudith @derosa__lisa and many more !

[Laurence Albiges @AlbigesL]

@TiansterZhang @KidneyCancer @MichaelStaehler @RCCadvocate @cnsternberg @montypal @tompowles1 @crisuarez08 Thanks for highlighting @CARE1Project - up and running in >30 sites in 🇫🇷 🇨🇿 & currently being activated across EU countries 🇳🇱 🇦🇹 soon in 🇬🇧 🇮🇹 🇩🇪 🇬🇷 🇧🇪 🇵🇹 🇫🇮
Special thanks @tompowles1 @ViktorGruenwald @crisuarez08 @g_develasco @IKCCorg @GustaveRoussy @AssoARTuR and all!

[Laurence Albiges @AlbigesL]

@KidneyCancer @minaseconomides @nachoduranm @TurajlicLab @LauraMarandino @macsrey @grantissimus Thanks for the invitation to this great Mentor -Mentee panel discussions #IKCSEU25 with @TurajlicLab @grantissimus
Huge thanks to @KidneyCancer for giving these opportunities to broadcast all the work of @GustaveRoussy young talents

[Kidney Cancer @KidneyCancer]

🎉 Excited to share that @derosa_lisa will be the Keynote Speaker at 2025 IKCS: Europe! #IKCSEU25

Don't miss her talk on the kidney cancer #microbiome. Register with discount rates till 4/10! https://t.co/UAzsbVfCxE

[Laurence Albiges @AlbigesL]

Day 1 @myESMO #Preceptorship in Metastatic #urothelial #RCC #cancer
62 participants from 26 countries selected out of >230 applicants ! Thanks to the faculty for sharing #SOC @myESMO #guidelines

[ESMO - Eur. Oncology @myESMO]

In his Keynote Lecture at #ELCC25, @BenjaminBesseMD discusses when ‘less is more,’ describing different de-escalation strategies to balance the efficacy versus toxicity of #CancerTreatment, particularly #immunotherapy

Read more in the #ESMODailyReporter🔗 https://t.co/QIDDrx5g3d

[Laurence Albiges @AlbigesL]

Today is a very special day for patients with RCC :
CHMP as approved BELZUTIFAN both for VHL disease associated RCC and for advanced renal cell carcinomas (following CPI and 2 VEGFR TKIs)
Data presented at @myESMO and published in @NEJM

[Sumanta K. Pal, MD, FASCO @montypal]

Please join @AlbigesL @g_develasco #JensBedkeMD & myself at #ESMO24 for a discussion of #kidneycancer that will span topics of #adjuvant & #metastatic dz tx. We have worked hard to incorporate discussion around data presented just a day earlier- incl perspectives on #TiNivo2, #SUNNIFORECAST, #LITESPARK005, as well as updates on #CM9ER, #CLEAR, #KN426 & other studies! See you Saturday evening at 6:30 pm!

[Morgan Roupret @MRoupret]

#BreakingNews‌ Our 2023 IF is now 8.3 ! So proud of our amazing team @AlbigesL @UroDocAsh @Ric_Campi @Ecastromarcos @jteoh_hk @CaPsurvivorship @RenuEapen @GPloussard @CathyJPierce @EurUrolOncol

[Brian Rini, MD @brian_rini]

KIM-1 is a novel prognostic and predictive biomarker in the adjuvant RCC space. Great data at #ASCO24 and stellar discussion by @VincentWenxinXu (Academy of Kidney Cancer Investigators member!). We discuss the KIM-1 data with @AlbigesL

https://t.co/bDsGpwGlFG

[Urology Times @UrologyTimes]

Circulating kidney injury molecule-1 may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma. #ASCO24 #kcsm @AlbigesL
https://t.co/fh4uQlCJBH

[Laurence Albiges @AlbigesL]

@DrChoueiri @montypal Tour de force of the amazing @montypal @cityofhope highlighting advances in papillary RCC, ChromophobeRCC, and many rare entities…. Major step forward with prospective phase II/III for pRCC @ASCO #ASCO24

[Laurence Albiges @AlbigesL]

@HHammersMD @VincentWenxinXu Thanks Hans !

[Toni Choueiri, MD @DrChoueiri]

Exciting preliminary data from Phase I/Ib study of HIF2α inhibitor DFF332 in pts w/ advanced ccRCC presented by my dear friend @montypal at #ASCO24: promising safety profile, indications of clinical activity, and dose-proportional modulation of EPO.

@ASCO @AlbigesL @OncoAlert @DanaFarber_GU

[Oncology Tube @oncologytube]

Top 5 Must See Kidney and Bladder Data @montypal #ASCO24 @ASCO @AlbigesL @brian_rini @motzermd @shilpaonc @CityofHope_GU @cityofhope Click Here for the Data Links: https://t.co/0RUwnXQw7M

[Paulo G Bergerot @PauloBergerot]

Don't miss tomorrow's Rapid Oral Abstract Session - Friday 8:30

@Montypal will present the Preliminary results of
P1 study monotherapy of DFF332: promising safety profile & have been indications of clinical activity
@ASCO #ASCO24
@AlbigesL

👉https://t.co/RIZevrilHu